Business
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data for the company’s
About this update from Veracyte, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif., and virtually, February 17-19, 2022.\n\nThe accepted abstracts include data from a phase 3 study evaluating the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from their diagnostic biopsy specimen. This is the first late-stage clinical study validating the use of any gene expression classifier as a prognostic biomarker in this setting.\n\n“At this year’s ASCO GU Symposium we look forward to sharing data from multiple studies that reinforce the ability of our Decipher genomic classifiers to guide more informed, individualized treatment for patients with urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “The findings offer new insights into how our tests may help physicians stratify risk and guide treatment decisions for their patients with prostate, bladder and kidney cancers.”\n\nBelow are details of the Veracyte abstracts, which will be presented as posters at the 2022 ASCO GU Cancers Symposium being held at Moscone Center. All poster sessions will take place in Moscone West, Level 1.\n\n\n\nDate/Time:\n\n\n\n\nFebruary 17, 2022, 11:30 a.m.-1:00 p.m. PST\n\n\n\n\n\nTitle:\n\n\n\n\nValidation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126\n\n\n\n\n\nPresenter:\n\n\n\n\nDaniel E. Spratt, M.D., Case Western Reserve University\n\n\n\n\n\nSession:\n\n\n\n\nPoster Session A\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nDate/Time:\n\n\n\n\nFebruary 17, 2022, 11:30 a.m.-1:00 p.m. PST\n\n\n\n\n\nTitle:\n\n\n\n\nComparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829-patient cohort\n\n\n\n\n\nPresenter:\n\n\n\n\nAdelene Sim, Ph.D., Duke-NUS Medical School\n\n\n\n\n\nSession:\n\n\n\n\nPoster Session A\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nDate/Time:\n\n\n\n\nFebruary 17, 2022, 11:30 a.m.-1:00 p.m. PST\n\n\n\n\n\nTitle:\n\n\n\n\nTranscriptomic Discriminators of Response to Apalutamide in Patients with Prostate Cancer (PC...